Clinical Trial Update: Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a bortezomib-based regimen for refractory or relapsed acute lymphoblastic leukemia, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: Instituto do Cancer do Estado de São Paulo | Conditions: Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission | Phase 2 | Status: RECRUITING